EloraTZP: Read the Combination Study
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

EloraTZP is Lilly's research name for combining eloralintide with tirzepatide. It describes a combination program rather than a new single peptide molecule. In September 2026, Lilly reported a forty-eight-week phase 2b study involving 367 adults with overweight or obesity and type 2 diabetes. The company reported larger numerical weight and A1C reductions with three of the four combinations than with tirzepatide alone. Gastrointestinal events occurred more frequently in the combination groups. These are sponsor-reported results that need full methodological scrutiny. They do not validate independently mixed products, and the tested population limits broader conclusions.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Lilly (30 September 2026): EloraTZP phase 2b results in adults with obesity or overweight and type 2 diabetes
https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
Official sponsor report of a primary clinical trial; not a peer-reviewed full report

EVIDENCE LIMITATIONS
This is explicitly a sponsor-reported result and not presented as independent peer-reviewed verification.
The primary endpoint compared weight change with placebo; the tirzepatide comparison was a secondary endpoint.
Different estimands, missing-data methods, discontinuations and final trial reports require review before numerical efficacy claims.
Do not generalize to seller blends or independently combined products.
The lowest-dose combination did not exceed tirzepatide alone on weight or A1C reduction in the reported efficacy-estimand table. Do not imply that all four combinations were superior.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
EloraTZP: What Combination Obesity Trials Are Designed to Learn